Immunogenicity of a third dose of the bnt162b2 covid-19 vaccine in patients with cll: effects on treatment selection

HIGHLIGHTS

• who: Panagiotis T. Diamantopoulos from the Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece have published the article: Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection, in the Journal: (JOURNAL) of October/12,/2021
• what: The authors assessed the immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL. Since the study was not designed to record COVID-19, but only immunogenicity results, there was no active monitoring for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.